Åslaug Helland
Åslaug Helland
Explore linked clinical trials.1 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, cancer, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-02-29 | NCT04300244 |